-
Using Scaling Factor Model to Estimate the Value Set of Psoriasis Bolt-On EQ-5D-5L Health States
Sep 18, 2025, 18:38 PM -
Evaluating Fertility Treatment Costs in Japan: A Micro-Costing Analysis
Sep 18, 2025, 18:38 PM -
Use of RWE to Inform Survival Extrapolation in Health Economic Appraisals of Cancer Drugs in Sweden: A Review of National Health Economic Reports 2010-2024
Sep 18, 2025, 18:38 PM -
Integrating Guidance Through a Whole Life-Cycle Approach: Wouldn’t It Be NICE?
Sep 9, 2025, 16:22 PM -
Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Dostarlimab Plus Carboplatin-Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer With Deficient Mismatch Repair (dMMR) and High Microsatellite Instability (MSI-H) in France
Sep 9, 2025, 16:22 PM -
Development of an AI-Powered Command-Line Agent to Support Methodological Guidance Selection in Health Economics Analysis
Sep 9, 2025, 16:22 PM -
Unlocking Value: Assessing the Cost-Effectiveness of Pitolisant Wakix®in Portugal
Sep 9, 2025, 16:22 PM -
Transforming Patient Journeys With Agentic AI
Sep 9, 2025, 16:22 PM -
Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Breast Cancer: A Systematic Literature Review (SLR)
Sep 9, 2025, 16:22 PM -
Ukraine’s First Horizon Scanning Pilot: Lessons for HTA Implementation
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Pan-European Severity Assessment Methods and Their Uncertainty in Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Persistence of Anticholinergic Agents in Patients With Overactive Bladder: A Cohort Study From the French National Health Insurance Claim Database (SNDS)
Sep 9, 2025, 16:22 PM -
Examination of Muscle Activity Among Aesthetic Sports Athletes
Sep 9, 2025, 16:22 PM -
Prevalence and Overlap of Overweight/Obesity Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease in England: A Clinical Practice Research Datalink Study
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Introducing the Elecsys® PRO-C3 Assay as Part of the ADAPT Algorithm for Assessing the Severity of Hepatic Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the UK
Sep 9, 2025, 16:22 PM -
The Budget Impact and Time Savings of Introducing Subcutaneously Administered Nivolumab and Hyaluronidase (NIVO SC) to Patients Receiving Intravenously Administered Nivolumab (NIVO IV) Across Indications in Canada
Sep 9, 2025, 16:22 PM -
Patient Perspectives on the Lifelong Impact of Preterm Birth in Chronic Respiratory Disease Care
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Levofloxacin for Tuberculosis Prevention in MDR/RR-TB Contacts in High-Burden Settings
Sep 9, 2025, 16:22 PM -
Does the Joint Clinical Assessment (JCA) Enable Health Equity Across Europe? A Review of HTA Practices in the EU
Sep 9, 2025, 16:22 PM
